• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重复使用抗生素与新冠病毒感染后的住院和死亡风险(OpenSAFELY):一项配对病例对照研究

Repeated antibiotic exposure and risk of hospitalisation and death following COVID-19 infection (OpenSAFELY): a matched case-control study.

作者信息

Yang Ya-Ting, Wong David, Ashcroft Darren M, Massey Jon, MacKenna Brian, Fisher Louis, Mehrkar Amir, Bacon Sebastian Cj, Hand Kieran, Zhong Xiaomin, Fahmi Ali, Goldacre Ben, van Staa Tjeerd, Palin Victoria

机构信息

Centre for Health Informatics, School of Health Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK.

Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds, UK.

出版信息

EClinicalMedicine. 2023 Jul 5;61:102064. doi: 10.1016/j.eclinm.2023.102064. eCollection 2023 Jul.

DOI:10.1016/j.eclinm.2023.102064
PMID:37528841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10388579/
Abstract

BACKGROUND

Identifying potential risk factors related to severe COVID-19 outcomes is important. Repeated intermittent antibiotic use is known be associated with adverse outcomes. This study aims to examine whether prior frequent antibiotic exposure is associated with severe COVID-19 outcomes.

METHODS

With the approval of NHS England, we used the OpenSAFELY platform, which integrated primary and secondary care, COVID-19 test, and death registration data. This matched case-control study included 0.67 million patients (aged 18-110 years) from an eligible 2.47 million patients with incident COVID-19 by matching with replacement. Inclusion criteria included registration within one general practice for at least 3 years and infection with incident COVID-19. Cases were identified according to different severity of COVID-19 outcomes. Cases and eligible controls were 1:6 matched on age, sex, region of GP practice, and index year and month of COVID-19 infection. Five quintile groups, based on the number of previous 3-year antibiotic prescriptions, were created to indicate the frequency of prior antibiotic exposure. Conditional logistic regression used to compare the differences between case and control groups, adjusting for ethnicity, body mass index, comorbidities, vaccination history, deprivation, and care home status. Sensitivity analyses were done to explore potential confounding and the effects of missing data.

FINDINGS

Based on our inclusion criteria, between February 1, 2020 and December 31, 2021, 98,420 patients were admitted to hospitals and 22,660 died. 55 unique antibiotics were prescribed. A dose-response relationship between number of antibiotic prescriptions and risk of severe COVID-19 outcome was observed. Patients in the highest quintile with history of prior antibiotic exposure had 1.80 times greater odds of hospitalisation compared to patients without antibiotic exposure (adjusted odds ratio [OR] 1.80, 95% Confidence Interval [CI] 1.75-1.84). Similarly, the adjusted OR for hospitalised patients with death outcomes was 1.34 (95% CI 1.28-1.41). Larger number of prior antibiotic type was also associated with more severe COVID-19 related hospital admission. The adjusted OR of quintile 5 exposure (the most frequent) with more than 3 antibiotic types was around 2 times larger than quintile 1 (only 1 type; OR 1.80, 95% CI 1.75-1.84 vs. OR 1.03, 95% CI 1.01-1.05).

INTERPRETATION

Our observational study has provided evidence that antibiotic exposure frequency and diversity may be associated with COVID-19 severity, potentially suggesting adverse effects of repeated intermittent antibiotic use. Future work could work to elucidate causal links and potential mechanisms. Antibiotic stewardship should put more emphasis on long-term antibiotic exposure and its adverse outcome to increase the awareness of appropriate antibiotics use.

FUNDING

Health Data Research UK and National Institute for Health Research.

摘要

背景

识别与新冠肺炎严重后果相关的潜在风险因素很重要。已知反复间歇性使用抗生素与不良后果相关。本研究旨在探讨既往频繁接触抗生素是否与新冠肺炎严重后果相关。

方法

在英国国家医疗服务体系(NHS)英格兰地区的批准下,我们使用了OpenSAFELY平台,该平台整合了初级和二级医疗、新冠肺炎检测及死亡登记数据。这项匹配病例对照研究通过匹配替换法,从符合条件的247万例新冠肺炎确诊患者中纳入了67万例患者(年龄在18至110岁之间)。纳入标准包括在同一全科诊所注册至少3年且感染新冠肺炎。根据新冠肺炎后果的不同严重程度确定病例。病例和符合条件的对照在年龄、性别、全科诊所所在地区以及新冠肺炎感染的索引年份和月份上进行1:6匹配。根据过去3年抗生素处方数量创建了五个五分位数组,以表明既往抗生素接触频率。使用条件逻辑回归比较病例组和对照组之间的差异,并对种族、体重指数、合并症、疫苗接种史、贫困程度和养老院状况进行调整。进行敏感性分析以探讨潜在的混杂因素和缺失数据的影响。

结果

根据我们的纳入标准,在2020年2月1日至2021年12月31日期间,98420例患者住院,22660例死亡。共开具了55种不同的抗生素。观察到抗生素处方数量与新冠肺炎严重后果风险之间存在剂量反应关系。与未接触抗生素的患者相比,既往有抗生素接触史的最高五分位数组患者住院几率高1.80倍(调整后的优势比[OR]为1.80,95%置信区间[CI]为1.75 - 1.84)。同样,因死亡结果住院患者的调整后OR为1.34(95%CI为1.28 - 1.41)。既往使用抗生素种类较多也与新冠肺炎相关住院更为严重有关。接触5种抗生素(最频繁)且超过3种抗生素类型的五分位数组的调整后OR比接触1种抗生素(仅1种类型)的五分位数组大2倍左右(OR为1.80,95%CI为1.75 - 1.84 对比 OR为1.03,95%CI为1.01 - 1.05)。

解读

我们的观察性研究提供了证据表明抗生素接触频率和多样性可能与新冠肺炎严重程度相关,这可能表明反复间歇性使用抗生素存在不良影响。未来的工作可以致力于阐明因果关系和潜在机制。抗生素管理应更加强调长期抗生素接触及其不良后果,以提高对抗生素合理使用的认识。

资助

英国健康数据研究中心和英国国家卫生研究院。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a6/10388579/3bb6eefa3878/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a6/10388579/88f963a4b8bc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a6/10388579/3bb6eefa3878/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a6/10388579/88f963a4b8bc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50a6/10388579/3bb6eefa3878/gr2.jpg

相似文献

1
Repeated antibiotic exposure and risk of hospitalisation and death following COVID-19 infection (OpenSAFELY): a matched case-control study.重复使用抗生素与新冠病毒感染后的住院和死亡风险(OpenSAFELY):一项配对病例对照研究
EClinicalMedicine. 2023 Jul 5;61:102064. doi: 10.1016/j.eclinm.2023.102064. eCollection 2023 Jul.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform.在英格兰,COVID-19 住院后整体和特定病因的住院和死亡:使用 OpenSAFELY 平台中的链接初级保健、二级保健和死亡登记数据进行的队列研究。
PLoS Med. 2022 Jan 25;19(1):e1003871. doi: 10.1371/journal.pmed.1003871. eCollection 2022 Jan.
4
Exploring Prior Antibiotic Exposure Characteristics for COVID-19 Hospital Admission Patients: OpenSAFELY.探索新冠病毒肺炎住院患者的既往抗生素暴露特征:OpenSAFELY研究。
Antibiotics (Basel). 2024 Jun 18;13(6):566. doi: 10.3390/antibiotics13060566.
5
Clinical and health inequality risk factors for non-COVID-related sepsis during the global COVID-19 pandemic: a national case-control and cohort study.全球新冠疫情期间非新冠相关脓毒症的临床及健康不平等风险因素:一项全国性病例对照及队列研究
EClinicalMedicine. 2023 Nov 23;66:102321. doi: 10.1016/j.eclinm.2023.102321. eCollection 2023 Dec.
6
Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform.在英格兰 1700 万成年人中,观察性队列研究使用 OpenSAFELY 平台发现 SARS-CoV-2 感染以及与 COVID-19 相关的住院、重症监护病房入院和死亡的种族差异。
Lancet. 2021 May 8;397(10286):1711-1724. doi: 10.1016/S0140-6736(21)00634-6. Epub 2021 Apr 30.
7
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.苏格兰 257 万人中 BNT162b2 和 ChAdOx1 nCoV-19 疫苗接种后 COVID-19 住院和死亡情况(EAVE II):一项前瞻性队列研究。
Lancet Respir Med. 2021 Dec;9(12):1439-1449. doi: 10.1016/S2213-2600(21)00380-5. Epub 2021 Sep 29.
8
Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.在奥密克戎毒株流行期间,使用OpenSAFELY平台进行的观察性队列研究:评估奈玛特韦/利托那韦与索托维单抗和莫努匹韦相比,在预防非住院高危患者出现严重新冠病毒病结局方面的有效性。
Lancet Reg Health Eur. 2023 Oct 8;34:100741. doi: 10.1016/j.lanepe.2023.100741. eCollection 2023 Nov.
9
Electronically delivered interventions to reduce antibiotic prescribing for respiratory infections in primary care: cluster RCT using electronic health records and cohort study.电子干预措施减少初级保健中呼吸道感染抗生素处方:使用电子健康记录的群组 RCT 和队列研究。
Health Technol Assess. 2019 Mar;23(11):1-70. doi: 10.3310/hta23110.
10
Impact of COVID-19 on broad-spectrum antibiotic prescribing for common infections in primary care in England: a time-series analyses using OpenSAFELY and effects of predictors including deprivation.2019年冠状病毒病对英格兰基层医疗中常见感染的广谱抗生素处方的影响:使用OpenSAFELY进行的时间序列分析以及包括贫困在内的预测因素的影响
Lancet Reg Health Eur. 2023 May 16;30:100653. doi: 10.1016/j.lanepe.2023.100653.

引用本文的文献

1
Exposure to suppressive antibiotic therapy in women with recurrent urinary tract infections and severity of infections: a retrospective population-based cohort study.复发性尿路感染女性接受抑制性抗生素治疗与感染严重程度:一项基于人群的回顾性队列研究。
BMJ Open. 2025 Aug 16;15(8):e098371. doi: 10.1136/bmjopen-2024-098371.
2
Gut microbe-host interactions in post-COVID syndrome: a debilitating or restorative partnership?新冠后综合征中的肠道微生物-宿主相互作用:是一种使人虚弱还是恢复性的伙伴关系?
Gut Microbes. 2024 Jan-Dec;16(1):2402544. doi: 10.1080/19490976.2024.2402544. Epub 2024 Sep 17.
3
Risk of emergency hospital admission related to adverse events after antibiotic treatment in adults with a common infection: impact of COVID-19 and derivation and validation of risk prediction models.

本文引用的文献

1
Addressing long-term and repeat antibiotic prescriptions in primary care: considerations for a behavioural approach.解决基层医疗中长期和重复使用抗生素处方的问题:行为学方法的考量
BMJ Qual Saf. 2022 Oct 19;31(11):782-786. doi: 10.1136/bmjqs-2022-014821.
2
A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2.高危肠道微生物群落与致命性的 SARS-CoV-2 过度炎症免疫和代谢反应相关联。
Gut Microbes. 2022 Jan-Dec;14(1):2073131. doi: 10.1080/19490976.2022.2073131.
3
Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019-June 2021).
成人常见感染后抗生素治疗相关不良事件导致急诊住院的风险:COVID-19 的影响及风险预测模型的建立和验证。
BMC Med. 2024 Jul 2;22(1):277. doi: 10.1186/s12916-024-03480-2.
4
Exploring Prior Antibiotic Exposure Characteristics for COVID-19 Hospital Admission Patients: OpenSAFELY.探索新冠病毒肺炎住院患者的既往抗生素暴露特征:OpenSAFELY研究。
Antibiotics (Basel). 2024 Jun 18;13(6):566. doi: 10.3390/antibiotics13060566.
5
Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation.儿童干细胞移植患者中菌群失调性肺损伤的病理生物学特征。
Nat Med. 2024 Jul;30(7):1982-1993. doi: 10.1038/s41591-024-02999-4. Epub 2024 May 23.
6
Clinical courses and outcomes of COVID-19 associated pulmonary aspergillosis in 168 patients with the SARS-CoV-2 omicron variant.168 例 SARS-CoV-2 奥密克戎变异株相关 COVID-19 肺曲霉病患者的临床病程和结局。
BMC Infect Dis. 2024 Jan 23;24(1):117. doi: 10.1186/s12879-023-08971-w.
7
Clinical and health inequality risk factors for non-COVID-related sepsis during the global COVID-19 pandemic: a national case-control and cohort study.全球新冠疫情期间非新冠相关脓毒症的临床及健康不平等风险因素:一项全国性病例对照及队列研究
EClinicalMedicine. 2023 Nov 23;66:102321. doi: 10.1016/j.eclinm.2023.102321. eCollection 2023 Dec.
8
Pulmonary microbiome and transcriptome signatures reveal distinct pathobiologic states associated with mortality in two cohorts of pediatric stem cell transplant patients.肺部微生物组和转录组特征揭示了与两组儿科干细胞移植患者死亡率相关的不同病理生物学状态。
medRxiv. 2023 Nov 29:2023.11.29.23299130. doi: 10.1101/2023.11.29.23299130.
新冠病毒患者的抗菌药物耐药性:系统评价和荟萃分析(2019 年 11 月至 2021 年 6 月)。
Antimicrob Resist Infect Control. 2022 Mar 7;11(1):45. doi: 10.1186/s13756-022-01085-z.
4
How did general practices organize care during the COVID-19 pandemic: the protocol of the cross-sectional PRICOV-19 study in 38 countries.在 COVID-19 大流行期间,全科医生如何组织护理:38 个国家的 PRICOV-19 研究的横断面研究方案。
BMC Prim Care. 2022 Jan 15;23(1):11. doi: 10.1186/s12875-021-01587-6.
5
Alterations of fecal antibiotic resistome in COVID-19 patients after empirical antibiotic exposure.新冠肺炎患者经验性抗生素暴露后粪便抗生素耐药组的改变。
Int J Hyg Environ Health. 2022 Mar;240:113882. doi: 10.1016/j.ijheh.2021.113882. Epub 2021 Dec 11.
6
Correlation between Previous Antibiotic Exposure and COVID-19 Severity. A Population-Based Cohort Study.既往抗生素暴露与新冠病毒病严重程度的相关性。一项基于人群的队列研究。
Antibiotics (Basel). 2021 Nov 8;10(11):1364. doi: 10.3390/antibiotics10111364.
7
COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea.免疫功能低下患者的 COVID-19 相关结局:韩国的一项全国性研究。
PLoS One. 2021 Oct 1;16(10):e0257641. doi: 10.1371/journal.pone.0257641. eCollection 2021.
8
Antibiotic overuse: managing uncertainty and mitigating against overtreatment.抗生素过度使用:应对不确定性并避免过度治疗
BMJ Qual Saf. 2022 Mar;31(3):163-167. doi: 10.1136/bmjqs-2021-013615. Epub 2021 Jul 20.
9
Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform.学习障碍人群因新冠病毒感染住院和死亡的风险:利用 OpenSAFELY 平台开展的基于人群的队列研究。
BMJ. 2021 Jul 14;374:n1592. doi: 10.1136/bmj.n1592.
10
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use.抗菌药物管理:有效使用抗菌药物的系统与流程
JAC Antimicrob Resist. 2019 Jul 18;1(2):dlz025. doi: 10.1093/jacamr/dlz025. eCollection 2019 Sep.